{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:49:57Z","timestamp":1774694997952,"version":"3.50.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11647-8","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:27:30Z","timestamp":1774686450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The diagnostic potential of nanobodies in acute myeloid leukemia"],"prefix":"10.1007","volume":"53","author":[{"given":"Amirhossein Faghih","family":"Ojaroodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danial","family":"Mahrooghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Dastbaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aydin","family":"Zohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narjes","family":"Seddighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"12","key":"11647_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"2","key":"11647_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A (2023) Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108(2):353\u2013366","journal-title":"Haematologica"},{"issue":"6","key":"11647_CR3","doi-asserted-by":"publisher","first-page":"e896","DOI":"10.1097\/HS9.0000000000000896","volume":"7","author":"C Tomasoni","year":"2023","unstructured":"Tomasoni C, Pievani A, Rambaldi B, Biondi A, Serafini M (2023) A Question of Frame: The Role of the Bone Marrow Stromal Niche in Myeloid Malignancies. Hemasphere 7(6):e896","journal-title":"Hemasphere"},{"issue":"2","key":"11647_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/13543784.2023.2179482","volume":"32","author":"JW Morse","year":"2023","unstructured":"Morse JW, Rios M, Ye J, Rios A, Zhang CC, Daver NG et al (2023) Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. Expert Opin Investig Drugs 32(2):107\u2013125","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"11647_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther 7(1):93","journal-title":"Signal Transduct Target Ther"},{"key":"11647_CR6","doi-asserted-by":"publisher","first-page":"204062072311547","DOI":"10.1177\/20406207231154708","volume":"14","author":"M Swaminathan","year":"2023","unstructured":"Swaminathan M, Cortes JE (2023) Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol 14:20406207231154708","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"11647_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, Nouri S, Hussen A, Bayani A, Khaksari MN, Soleimani Samarkhazan H (2025) Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Experimental Med 25(1):166","journal-title":"Clin Experimental Med"},{"issue":"1","key":"11647_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","volume":"22","author":"E Alexander","year":"2024","unstructured":"Alexander E, Leong KW (2024) Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years. J Nanobiotechnol 22(1):661","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"11647_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/imr.13381","volume":"328","author":"T Yu","year":"2024","unstructured":"Yu T, Zheng F, He W, Muyldermans S, Wen Y (2024) Single domain antibody: Development and application in biotechnology and biopharma. Immunol Rev 328(1):98\u2013112","journal-title":"Immunol Rev"},{"issue":"9","key":"11647_CR10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/bloodadvances.2023011858","volume":"8","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Roobrouck A, Deschamps G, Bonnevaux H, Guerif S, De Brabandere V et al (2024) Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Adv 8(9):2059\u20132073","journal-title":"Blood Adv"},{"key":"11647_CR11","doi-asserted-by":"publisher","first-page":"100751","DOI":"10.1016\/j.omto.2023.100751","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T et al (2023) Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics 31:100751","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"11647_CR12","doi-asserted-by":"publisher","first-page":"200949","DOI":"10.1016\/j.omton.2025.200949","volume":"33","author":"F Bernasconi-Bisio","year":"2025","unstructured":"Bernasconi-Bisio F, Molina E, Ibarra V, Ib\u00e1\u00f1ez-Sala I, Rochira F, Jauregui P et al (2025) Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. Mol Ther Oncol 33(1):200949","journal-title":"Mol Ther Oncol"},{"issue":"5","key":"11647_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12185-024-03848-3","volume":"120","author":"Y Ishikawa","year":"2024","unstructured":"Ishikawa Y (2024) Recent progress in AML with recurrent genetic abnormalities. Int J Hematol 120(5):525\u2013527","journal-title":"Int J Hematol"},{"issue":"7","key":"11647_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"11","key":"11647_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"2","key":"11647_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci 111(2):312\u2013322","journal-title":"Cancer Sci"},{"issue":"4","key":"11647_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"11","key":"11647_CR18","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","volume":"36","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE et al (2022) Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729\u20132733","journal-title":"Leukemia"},{"issue":"7954","key":"11647_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M et al (2023) The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615(7954):920\u2013924","journal-title":"Nature"},{"issue":"11","key":"11647_CR20","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V et al (2024) Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood 144(11):1206\u20131220","journal-title":"Blood"},{"issue":"2","key":"11647_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ (2022) Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol 196(2):316\u2013328","journal-title":"Br J Haematol"},{"issue":"1","key":"11647_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjh.19519","volume":"205","author":"WY Jen","year":"2024","unstructured":"Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ et al (2024) Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol 205(1):30\u201347","journal-title":"Br J Haematol"},{"issue":"15","key":"11647_CR23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, Estey EH, L\u00f6wenberg B, Naoe T et al (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133(15):1630\u20131643","journal-title":"Blood"},{"issue":"5","key":"11647_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377(5):454\u2013464","journal-title":"N Engl J Med"},{"issue":"10388","key":"11647_CR25","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P et al (2023) Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10388):1571\u20131583","journal-title":"Lancet"},{"issue":"7397","key":"11647_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397):260\u2013263","journal-title":"Nature"},{"issue":"30","key":"11647_CR27","doi-asserted-by":"publisher","first-page":"47018","DOI":"10.18632\/oncotarget.10147","volume":"7","author":"F Chen","year":"2016","unstructured":"Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H (2016) Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget 7(30):47018\u201347032","journal-title":"Oncotarget"},{"issue":"12","key":"11647_CR28","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/leu.2016.237","volume":"30","author":"V Madan","year":"2016","unstructured":"Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J et al (2016) Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia 30(12):2430","journal-title":"Leukemia"},{"issue":"10","key":"11647_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ajh.25573","volume":"94","author":"L Iaccarino","year":"2019","unstructured":"Iaccarino L, Ottone T, Alfonso V, Cicconi L, Divona M, Lavorgna S et al (2019) Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. Am J Hematol 94(10):1091\u20131097","journal-title":"Am J Hematol"},{"issue":"6","key":"11647_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s12185-013-1354-4","volume":"97","author":"A Tomita","year":"2013","unstructured":"Tomita A, Kiyoi H, Naoe T (2013) Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol 97(6):717\u2013725","journal-title":"Int J Hematol"},{"issue":"10","key":"11647_CR31","doi-asserted-by":"publisher","first-page":"e0204850","DOI":"10.1371\/journal.pone.0204850","volume":"13","author":"H Hattori","year":"2018","unstructured":"Hattori H, Ishikawa Y, Kawashima N, Akashi A, Yamaguchi Y, Harada Y et al (2018) Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia. PLoS ONE 13(10):e0204850","journal-title":"PLoS ONE"},{"issue":"1","key":"11647_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-023-00975-8","volume":"14","author":"FM Tien","year":"2024","unstructured":"Tien FM, Yao CY, Tsai XC, Lo MY, Chen CY, Lee WH et al (2024) Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations. Blood Cancer J 14(1):15","journal-title":"Blood Cancer J"},{"issue":"5","key":"11647_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ccr.2009.09.036","volume":"16","author":"O Bereshchenko","year":"2009","unstructured":"Bereshchenko O, Mancini E, Moore S, Bilbao D, M\u00e5nsson R, Luc S et al (2009) Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C\/EBPalpha mutant AML. Cancer Cell 16(5):390\u2013400","journal-title":"Cancer Cell"},{"issue":"8","key":"11647_CR34","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","volume":"117","author":"E Taskesen","year":"2011","unstructured":"Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ et al (2011) Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117(8):2469\u20132475","journal-title":"Blood"},{"key":"11647_CR35","unstructured":"Tripathi A, Chuda R (2025) Laboratory Evaluation of Acute Leukemia. StatPearls"},{"issue":"22","key":"11647_CR36","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.3390\/cancers16223855","volume":"16","author":"F Ally","year":"2024","unstructured":"Ally F, Chen X (2024) Acute myeloid leukemia: diagnosis and evaluation by flow cytometry. Cancers 16(22):3855","journal-title":"Cancers"},{"issue":"1","key":"11647_CR37","doi-asserted-by":"publisher","first-page":"9585","DOI":"10.1038\/s41598-022-13545-y","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Xing S, Zhang H, Mao X, Xiao M, Wang Y (2022) FISH improves risk stratification in acute leukemia by identifying KMT2A abnormal copy number and rearrangements. Sci Rep 12(1):9585","journal-title":"Sci Rep"},{"issue":"1","key":"11647_CR38","first-page":"4","volume":"19","author":"D Qin","year":"2022","unstructured":"Qin D (2022) Molecular testing for acute myeloid leukemia. Cancer Biology Med 19(1):4\u201313","journal-title":"Cancer Biology Med"},{"issue":"2","key":"11647_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/hematolrep17020018","volume":"17","author":"L Pratiwi","year":"2025","unstructured":"Pratiwi L, Mashudi FH, Ningtyas MC, Sutanto H, Romadhon PZ (2025) Genetic profiling of acute and chronic leukemia via next-generation sequencing: current insights and future perspectives. Hematol Rep 17(2):18","journal-title":"Hematol Rep"},{"issue":"1","key":"11647_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82(1):775\u2013797","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"11647_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41594-018-0028-6","volume":"25","author":"C McMahon","year":"2018","unstructured":"McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX et al (2018) Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol 25(3):289\u2013296","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"11647_CR42","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1038\/s41467-024-48735-x","volume":"15","author":"T Eden","year":"2024","unstructured":"Eden T, Schaffrath AZ, Wesolowski J, St\u00e4hler T, Tode N, Richter N et al (2024) Generation of nanobodies from transgenic \u2018LamaMice\u2019lacking an endogenous immunoglobulin repertoire. Nat Commun 15(1):4728","journal-title":"Nat Commun"},{"issue":"9","key":"11647_CR43","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00216-019-01633-4","volume":"411","author":"J-P Salvador","year":"2019","unstructured":"Salvador J-P, Vilaplana L, Marco M-P (2019) Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem 411(9):1703\u20131713","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"11647_CR44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/08820139.2010.542228","volume":"40","author":"F Rahbarizadeh","year":"2011","unstructured":"Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z (2011) Nanobody; an old concept and new vehicle for immunotargeting. Immunol Investig 40(3):299\u2013338","journal-title":"Immunol Investig"},{"issue":"1","key":"11647_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","volume":"23","author":"H Li","year":"2025","unstructured":"Li H, Zhou Q, Cao N, Hu C, Wang J, He Y et al (2025) Nanobodies and their derivatives: pioneering the future of cancer immunotherapy. Cell Communication Signal 23(1):271","journal-title":"Cell Communication Signal"},{"key":"11647_CR46","doi-asserted-by":"publisher","first-page":"911080","DOI":"10.3389\/fimmu.2022.911080","volume":"13","author":"J Caers","year":"2022","unstructured":"Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K et al (2022) Radiotheranostic agents in hematological malignancies. Front Immunol 13:911080","journal-title":"Front Immunol"},{"issue":"2","key":"11647_CR47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/2211-5463.13850","volume":"15","author":"NS El Salamouni","year":"2025","unstructured":"El Salamouni NS, Cater JH, Spenkelink LM, Yu H (2025) Nanobody engineering: computational modelling and design for biomedical and therapeutic applications. FEBS Open Bio 15(2):236\u2013253","journal-title":"FEBS Open Bio"},{"issue":"6","key":"11647_CR48","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"B-k Jin","year":"2023","unstructured":"Jin B-k, Odongo S, Radwanska M, Magez S (2023) NANOBODIES\u00ae: a review of generation, diagnostics and therapeutics. Int J Mol Sci 24(6):5994","journal-title":"Int J Mol Sci"},{"key":"11647_CR49","doi-asserted-by":"crossref","unstructured":"Yuan Y, Zhuoga C, Zeng C, Zhou W, Chen W, Zhen X, Jiang X (2025) Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy. Polymer Science & Technology","DOI":"10.1021\/polymscitech.5c00080"},{"issue":"1","key":"11647_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"R-M Lu","year":"2020","unstructured":"Lu R-M, Hwang Y-C, Liu I-J, Lee C-C, Tsai H-Z, Li H-J, Wu H-C (2020) Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 27(1):1","journal-title":"J Biomed Sci"},{"issue":"8","key":"11647_CR51","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583\u2013592","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"11647_CR52","first-page":"109","volume":"24","author":"I Hernandez","year":"2018","unstructured":"Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, Shrank WH (2018) Pricing of monoclonal antibody therapies: higher if used for cancer. Am J Manag Care 24(2):109\u2013112","journal-title":"Am J Manag Care"},{"issue":"3","key":"11647_CR53","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jconrel.2013.08.298","volume":"172","author":"S Oliveira","year":"2013","unstructured":"Oliveira S, Heukers R, Sornkom J, Kok RJ, Henegouwen PMvB (2013) Targeting tumors with nanobodies for cancer imaging and therapy. J Controlled Release 172(3):607\u2013617","journal-title":"J Controlled Release"},{"issue":"6","key":"11647_CR54","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3892\/ijo.2015.3210","volume":"47","author":"R Tsumura","year":"2015","unstructured":"Tsumura R, Sato R, Furuya F, Koga Y, Yamamoto Y, Fujiwara Y et al (2015) Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool. Int J Oncol 47(6):2107\u20132114","journal-title":"Int J Oncol"},{"issue":"4","key":"11647_CR55","first-page":"411","volume":"23","author":"MP Kelly","year":"2008","unstructured":"Kelly MP, Lee F-T, Tahtis K, Power BE, Smyth FE, Brechbiel MW et al (2008) Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm 23(4):411\u2013424","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"11647_CR56","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1083\/jcb.201409074","volume":"209","author":"J Helma","year":"2015","unstructured":"Helma J, Cardoso MC, Muyldermans S, Leonhardt H (2015) Nanobodies and recombinant binders in cell biology. J Cell Biol 209(5):633\u2013644","journal-title":"J Cell Biol"},{"key":"11647_CR57","doi-asserted-by":"crossref","unstructured":"Nelson AL (ed) (2010) editor Antibody fragments: hope and hype. Taylor & Francis, MAbs","DOI":"10.4161\/mabs.2.1.10786"},{"issue":"18","key":"11647_CR58","doi-asserted-by":"publisher","first-page":"9778","DOI":"10.3390\/ijms22189778","volume":"22","author":"DB Naidoo","year":"2021","unstructured":"Naidoo DB, Chuturgoon AA (2021) Nanobodies enhancing cancer visualization, diagnosis and therapeutics. Int J Mol Sci 22(18):9778","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11647_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41181-023-00194-3","volume":"8","author":"J Dewulf","year":"2023","unstructured":"Dewulf J, Flieswasser T, Delahaye T, Vangestel C, Miranda A, de Haard H et al (2023) Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharmacy Chem 8(1):8","journal-title":"EJNMMI Radiopharmacy Chem"},{"issue":"1","key":"11647_CR60","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/ijms21010310","volume":"21","author":"E Rom\u00e3o","year":"2020","unstructured":"Rom\u00e3o E, Krasniqi A, Maes L, Vandenbrande C, Sterckx YG-J, Stijlemans B et al (2020) Identification of nanobodies against the acute myeloid leukemia marker CD33. Int J Mol Sci 21(1):310","journal-title":"Int J Mol Sci"},{"issue":"7","key":"11647_CR61","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.7150\/thno.91456","volume":"14","author":"N Vandewalle","year":"2024","unstructured":"Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof TW et al (2024) AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia. Theranostics 14(7):2656","journal-title":"Theranostics"},{"key":"11647_CR62","doi-asserted-by":"crossref","unstructured":"Traenkle B, Rothbauer U (2017) Under the Microscope: Single-Domain Antibodies for Live-Cell Imaging and Super-Resolution Microscopy. Front Immunol 8","DOI":"10.3389\/fimmu.2017.01030"},{"issue":"11","key":"11647_CR63","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.tcb.2009.08.002","volume":"19","author":"EL Snapp","year":"2009","unstructured":"Snapp EL (2009) Fluorescent proteins: a cell biologist\u2019s user guide. Trends Cell Biol 19(11):649\u2013655","journal-title":"Trends Cell Biol"},{"issue":"4","key":"11647_CR64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nmeth.2377","volume":"10","author":"C Stadler","year":"2013","unstructured":"Stadler C, Rexhepaj E, Singan VR, Murphy RF, Pepperkok R, Uhl\u00e9n M et al (2013) Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells. Nat Methods 10(4):315\u2013323","journal-title":"Nat Methods"},{"issue":"11","key":"11647_CR65","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.bbapap.2014.04.019","volume":"1844","author":"PD Kaiser","year":"2014","unstructured":"Kaiser PD, Maier J, Traenkle B, Emele F, Rothbauer U (2014) Recent progress in generating intracellular functional antibody fragments to target and trace cellular components in living cells. Biochim Biophys Acta 1844(11):1933\u20131942","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"11647_CR66","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/cm.21122","volume":"70","author":"I Van Audenhove","year":"2013","unstructured":"Van Audenhove I, Van Impe K, Ruano-Gallego D, De Clercq S, De Muynck K, Vanloo B et al (2013) Mapping cytoskeletal protein function in cells by means of nanobodies. Cytoskeleton 70(10):604\u2013622","journal-title":"Cytoskeleton"},{"key":"11647_CR67","doi-asserted-by":"publisher","first-page":"e16228","DOI":"10.7554\/eLife.16228","volume":"5","author":"S Moutel","year":"2016","unstructured":"Moutel S, Bery N, Bernard V, Keller L, Lemesre E, De Marco A et al (2016) NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife 5:e16228","journal-title":"Elife"},{"key":"11647_CR68","doi-asserted-by":"crossref","unstructured":"Zolghadr K, Rothbauer U, Leonhardt H (2011) The fluorescent two-hybrid (F2H) assay for direct analysis of protein\u2013protein interactions in living cells. Two Hybrid Technologies: Methods and Protocols: Springer; pp. 275\u2009\u2013\u200982","DOI":"10.1007\/978-1-61779-455-1_16"},{"key":"11647_CR69","doi-asserted-by":"crossref","unstructured":"Pellis M, Muyldermans S, Vincke C (2012) Bacterial two hybrid: a versatile one-step intracellular selection method. Single Domain Antibodies: Methods and Protocols: Springer; pp. 135\u2009\u2013\u200950","DOI":"10.1007\/978-1-61779-968-6_9"},{"issue":"8","key":"11647_CR70","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ijc.26145","volume":"129","author":"RC Roovers","year":"2011","unstructured":"Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM et al (2011) A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer 129(8):2013\u20132024","journal-title":"Int J Cancer"},{"key":"11647_CR71","doi-asserted-by":"crossref","unstructured":"Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L et al (eds) (2014) Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. Taylor & Francis, MAbs","DOI":"10.4161\/19420862.2014.975099"},{"issue":"2","key":"11647_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbt.2012.09.002","volume":"30","author":"M Behdani","year":"2013","unstructured":"Behdani M, Zeinali S, Karimipour M, Khanahmad H, Schoonooghe S, Aslemarz A et al (2013) Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. New Biotechnol 30(2):205\u2013209","journal-title":"New Biotechnol"},{"key":"11647_CR73","doi-asserted-by":"crossref","unstructured":"van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y et al (2012) Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences 109(41):16642-7","DOI":"10.1073\/pnas.1202832109"},{"issue":"8","key":"11647_CR74","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-03-3935","volume":"64","author":"V Cortez-Retamozo","year":"2004","unstructured":"Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H (2004) Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64(8):2853\u20132857","journal-title":"Cancer Res"},{"issue":"02","key":"11647_CR75","doi-asserted-by":"publisher","first-page":"2230005","DOI":"10.1142\/S1793545822300051","volume":"15","author":"Y Yu","year":"2022","unstructured":"Yu Y, Yu J, Huang Z-L, Zhou F (2022) Application of super-resolution fluorescence microscopy in hematologic malignancies. J Innovative Opt Health Sci 15(02):2230005","journal-title":"J Innovative Opt Health Sci"},{"issue":"23","key":"11647_CR76","doi-asserted-by":"publisher","first-page":"34070","DOI":"10.18632\/oncotarget.8710","volume":"7","author":"J Tang","year":"2016","unstructured":"Tang J, Li J, Zhu X, Yu Y, Chen D, Yuan L et al (2016) Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget 7(23):34070","journal-title":"Oncotarget"},{"key":"11647_CR77","doi-asserted-by":"publisher","first-page":"153303382110101","DOI":"10.1177\/15330338211010117","volume":"20","author":"W Kang","year":"2021","unstructured":"Kang W, Ding C, Zheng D, Ma X, Yi L, Tong X et al (2021) Nanobody Conjugates for Targeted Cancer Therapy and Imaging. Technol Cancer Res Treat 20:15330338211010117","journal-title":"Technol Cancer Res Treat"},{"key":"11647_CR78","doi-asserted-by":"crossref","unstructured":"Soleimani Samarkhazan H, Khaksari MN, Mirzazadeh A, Siavashi M, Pilehvari N, Mohammadi MH (2025) Nanosensors in Leukemia Management: Pioneering Real-Time Biomarker Detection for Precision Oncology. Nano Select. :e70039","DOI":"10.1002\/nano.70039"},{"issue":"5","key":"11647_CR79","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/biom11050637","volume":"11","author":"L Berland","year":"2021","unstructured":"Berland L, Kim L, Abousaway O, Mines A, Mishra S, Clark L et al (2021) Nanobodies for medical imaging: about ready for prime time? Biomolecules 11(5):637","journal-title":"Biomolecules"},{"key":"11647_CR80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.iotech.2020.07.001","volume":"7","author":"M Rashidian","year":"2020","unstructured":"Rashidian M, Ploegh H (2020) Nanobodies as non-invasive imaging tools. Immuno-Oncology Technol 7:2\u201314","journal-title":"Immuno-Oncology Technol"},{"key":"11647_CR81","doi-asserted-by":"publisher","first-page":"838082","DOI":"10.3389\/fimmu.2021.838082","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Kang G, Yuan H, Cao X, Huang H, De Marco A (2022) Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment. Front Immunol 12:838082","journal-title":"Front Immunol"},{"issue":"3","key":"11647_CR82","first-page":"e54","volume":"2","author":"Q Su","year":"2023","unstructured":"Su Q, Shi W, Huang X, Yin S, Yang X, Lu X (2023) Recent advances of nanobody applications in diagnosis and detection. MedComm\u2013Biomaterials Appl 2(3):e54","journal-title":"MedComm\u2013Biomaterials Appl"},{"issue":"12","key":"11647_CR83","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1007\/s00259-023-06313-1","volume":"50","author":"L Li","year":"2023","unstructured":"Li L, Lin X, Wang L, Ma X, Zeng Z, Liu F et al (2023) Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga] Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging 50(12):3735\u20133749","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"11647_CR84","doi-asserted-by":"publisher","first-page":"7601","DOI":"10.1021\/acs.jmedchem.0c00418","volume":"63","author":"L Rosenfeld","year":"2020","unstructured":"Rosenfeld L, Sananes A, Zur Y, Cohen S, Dhara K, Gelkop S et al (2020) Nanobodies targeting prostate-specific membrane antigen for the imaging and therapy of prostate cancer. J Med Chem 63(14):7601\u20137615","journal-title":"J Med Chem"},{"key":"11647_CR85","doi-asserted-by":"crossref","unstructured":"Zeven K, Dierick H, Sevenois M, Baudhuin H, Navarro L, Van den Block S et al (2025) Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers. Eur J Nucl Med Mol Imaging. :1\u201313","DOI":"10.1007\/s00259-025-07205-2"},{"issue":"1","key":"11647_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13058-024-01803-y","volume":"26","author":"L Zhao","year":"2024","unstructured":"Zhao L, Xing Y, Liu C, Ma S, Huang W, Cheng Z, Zhao J (2024) Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial. Breast Cancer Res 26(1):40","journal-title":"Breast Cancer Res"},{"issue":"2","key":"11647_CR87","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2967\/jnumed.123.266254","volume":"65","author":"O Gondry","year":"2024","unstructured":"Gondry O, Caveliers V, Xavier C, Raes L, Vanhoeij M, Verfaillie G et al (2024) Phase II trial assessing the repeatability and tumor uptake of [68Ga] Ga-HER2 single-domain antibody PET\/CT in patients with breast carcinoma. J Nucl Med 65(2):178\u2013184","journal-title":"J Nucl Med"},{"issue":"1","key":"11647_CR88","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, Abosaoda MK, Rizaev J, Nazari M, Jafari Z, Soleimani Samarkhazan H (2025) Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Experimental Med 25(1):186","journal-title":"Clin Experimental Med"},{"issue":"3","key":"11647_CR89","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1039\/D1CB00023C","volume":"2","author":"TJ Harmand","year":"2021","unstructured":"Harmand TJ, Islam A, Pishesha N, Ploegh HL (2021) Nanobodies as in vivo, non-invasive, imaging agents. RSC Chem biology 2(3):685\u2013701","journal-title":"RSC Chem biology"},{"issue":"1","key":"11647_CR90","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12951-025-03868-z","volume":"23","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhou M, Lu C, Zhao P, Shi N, Zhou Y et al (2025) A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation. J Nanobiotechnol 23(1):734","journal-title":"J Nanobiotechnol"},{"issue":"19","key":"11647_CR91","doi-asserted-by":"publisher","first-page":"10745","DOI":"10.3390\/ijms221910745","volume":"22","author":"I Hrynchak","year":"2021","unstructured":"Hrynchak I, Santos L, Falc\u00e3o A, Gomes CM, Abrunhosa AJ (2021) Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies. Int J Mol Sci 22(19):10745","journal-title":"Int J Mol Sci"},{"issue":"10","key":"11647_CR92","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1007\/s00259-025-07205-2","volume":"52","author":"K Zeven","year":"2025","unstructured":"Zeven K, Dierick H, Sevenois M, Baudhuin H, Navarro L, Van den Block S et al (2025) Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers. Eur J Nucl Med Mol Imaging 52(10):3833\u20133845","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"05","key":"11647_CR93","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1055\/s-0043-1764369","volume":"44","author":"MD Sekar","year":"2023","unstructured":"Sekar MD, Raj M, Manivannan P (2023) Role of morphology in the diagnosis of acute leukemias: Systematic review. Indian J Med Pediatr Oncol 44(05):464\u2013473","journal-title":"Indian J Med Pediatr Oncol"},{"issue":"12","key":"11647_CR94","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","volume":"107","author":"JS Blachly","year":"2022","unstructured":"Blachly JS, Walter RB, Hourigan CS (2022) The present and future of measurable residual disease testing in acute myeloid leukemia. Haematologica 107(12):2810","journal-title":"Haematologica"},{"issue":"1","key":"11647_CR95","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.surg.2020.02.020","volume":"168","author":"TM Lwin","year":"2020","unstructured":"Lwin TM, Hernot S, Hollandsworth H, Amirfakhri S, Filemoni F, Debie P et al (2020) Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer. Surgery 168(1):85\u201391","journal-title":"Surgery"},{"issue":"7","key":"11647_CR96","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jso.26623","volume":"124","author":"TM Lwin","year":"2021","unstructured":"Lwin TM, Turner MA, Amirfakhri S, Nishino H, Debie P, Cosman BC et al (2021) Rapid tumor-labeling kinetics with a site\u2010specific near\u2010infrared anti\u2010CEA nanobody in a patient\u2010derived orthotopic xenograft mouse model of colon cancer. J Surg Oncol 124(7):1121\u20131127","journal-title":"J Surg Oncol"},{"issue":"9","key":"11647_CR97","doi-asserted-by":"publisher","first-page":"13006","DOI":"10.18632\/aging.202981","volume":"13","author":"S Qin","year":"2021","unstructured":"Qin S, Yu Y, Guan H, Yang Y, Sun F, Sun Y et al (2021) A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody. Aging 13(9):13006","journal-title":"Aging"},{"issue":"3","key":"11647_CR98","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cancers13030428","volume":"13","author":"E Renard","year":"2021","unstructured":"Renard E, Collado Camps E, Canovas C, Kip A, Gotthardt M, Rijpkema M et al (2021) Site-specific dual-labeling of a VHH with a chelator and a photosensitizer for nuclear imaging and targeted photodynamic therapy of EGFR-positive tumors. Cancers 13(3):428","journal-title":"Cancers"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11647-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:02:43Z","timestamp":1774692163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11647-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11647"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11647-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}}],"article-number":"554"}}